New Dual-Action immunotherapy trial offers hope for aggressive breast cancer

NCT ID NCT07178171

Summary

This study is testing whether a new immunotherapy drug called QL1706 works better when combined with different chemotherapy approaches for early-stage triple-negative breast cancer. The trial will enroll 30 patients who will receive either QL1706 with one type of chemotherapy or QL1706 with another type of chemotherapy. Researchers want to see if they can reduce the amount of chemotherapy needed while still effectively treating this aggressive cancer type.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TNBC, TRIPLE NEGATIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Xijing hospital

    RECRUITING

    Xi'an, Shaanxi, 710032, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.